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MyomiRsEpigenetics is defined as heritable information other than the DNA sequence itself. The concept implies that the
regulation of gene expression is a highly complex process in which epigenetics plays a major role that ranges
from fine-tuning to permanent gene activation/deactivation. Skeletal muscle is the main tissue involved in loco-
motion and energymetabolism in the body, accounting for at least 40% of the bodymass. Bodymass and function
vary according to age but also quickly adapt to both physiological and pathological cues. Besides transcriptional
mechanisms that controlmuscle differentiation, postnatal growth and remodeling, there are numerous epigenet-
ic mechanisms of regulation that modulate muscle gene expression. In this review, we describe and discuss only
some of the mechanisms underlying epigenetic regulation, such as DNA methylation, histone modifications and
microRNAs, which we believe are crucial to skeletal muscle development and disease.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
By combining the words “epi-” and “genetics”, the term epigenetics
originally suggested the idea that phenotypes arise from genotype
through programmed changes induced by the environment [1]. Nowa-
days epigenetics is used to define changes in gene expression or cellular
phenotype caused by mechanisms other than modifications in the DNA
sequence. One example of such mechanisms is chromatin modifica-
tions, such as DNA methylation and histone modifications. Generally,
DNAmethylation confers long-term epigenetic silencing of transposons
or imprinted genes in somatic cells, while histone marks confer short-
term, flexible, epigenetic silencing of genes that are required later in
development [2,3]. More recent findings have identified additional
epigenetic mechanisms responsible for cellular diversity via small regu-
latory non-coding RNAs [4,5]. These molecules modulate translation of
mRNAs by acting in a sequence-specific fashion. Epigenetic changes
are preserved when cells divide. When epigenetic changes occur in
sperm or egg cells that lead to fertilization, epigenetic changes are
inherited by the offspring.
Interest in epigenetic mechanisms has grown considerably in recent
years. As occurred with the Genome Project for widespreadmapping of
the genome,major efforts have been invested into shedding light on the
epigenome and into definingwhere epigeneticmodifications are located
within the genome. For instance, about 15 billion sites in the humanof Histology and Medical
nio Scarpa, 14, 00161 Rome,
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. This is an open access article undergenome that may be modified by DNA methylation have been identi-
fied; in addition, more than 1600 sense-anti-sense gene pairs are be-
lieved to be transcribed, indicating that more than 8% of the estimated
40,000 human genes have an antisense partner [6]. These findings
have laid the bases for studies on the post-transcriptional modulation
of gene expression via epigenetic regulation.
2. DNA methylation and gene imprinting
DNA methylation is an epigenetic mechanism that controls gene
expression and is associated with a number of key processes including
genomic imprinting and X-chromosome inactivation. DNAmethylation
mainly occurs on CpG dinucleotides inmammals, although recent stud-
ies have highlighted the presence of DNAmethylation at non-CpG sites,
which is capable of regulating gene expression in adult mammalian
somatic cells, including skeletal muscle cells [7]. DNA methylation
distinguishes the paternal from the maternal gene copy in genomic
imprinting. The repressed allele is methylated, whereas the active allele
is unmethylated [8] (Fig. 1). Imprinted genes do not rely on Mendelian
laws, according to which both parental copies are equally likely to
contribute to the outcome. An established hypothesis for the evolution
of gene imprinting is that the choice of which single allele of the gene
is expressed, i.e. the maternal or the paternal one, is fully beneficial to
the offspring when derived from one parent but has an inherent fitness
cost, in terms of ability to survive and reproduce,when derived from the
other parent [9]. According to this hypothesis, paternally expressed
genes tend to promote growth, whereas maternally imprinted genes
tend to be growth limiting because the mother needs to conserve
resources for her own survival and for that of her litter [10]. Intriguingly,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. DNA methylation and gene imprinting. DNA methylation is a biochemical process whereby a methyl group is added to the cytosine or adenine DNA nucleotides by DNA
methyltransferase (DNMT) enzyme. Upon DNAmethylation, gene transcription is repressed. Some DNAmethylations are heritable and cause genomic imprinting, as in the case
of Pw1/Peg3 allele.
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cells [11]. Many parentally imprinted genes are expressed at high levels
in fetal and newborn tissues and decline within weeks of birth in mice
[12,13]. Others, such as Pw1/Peg3, are expressed in adult somatic
stem cells though not in their differentiated progeny [14,15]. Dysregula-
tion of the expression of Pw1/Peg3 inmice reveals the critical role of this
gene in themaintenance of stem cells and skeletal muscle mass [15,16].
Pw1/Peg3 is a mediator of TNF-alpha and p53 pathways [17,18], which
are crucial players in the regulation of skeletal muscle homeostasis.
Transgenicmice for thedominant-negative formof Pw1/Peg3 are small-
er, with atrophic skeletal muscles characterized by significantly fewer
quiescent satellite cells but more activated euchromatic satellite cells
than those of controls [18]. In addition to its role in satellite cell behav-
ior, in vivo studies on tumor bearingmice have clarified the role of Pw1/
Peg3 in mediating p53-dependent myofiber atrophy in response to
cancer [18]. More recently, Pw1/Peg3 has been established as an invalu-
able marker for competent self-renewing stem cells in a wide range of
adult tissues: from the intestine to the seminiferous tubules, from the
bone to the central nervous system [14,19]. Thus, an incorrect genomic
imprinting and expression pattern of a single, specific methylated gene,
such as Pw1/Peg3, may have devastating consequences on tissue
homeostasis. Indeed, many skeletalmuscle diseases have been associat-
ed with defects in imprinted genes. Loss of methylation at several CpG
dinucleotides on the maternal imprinted gene epsilon-sarcoglycan
leads to biallelic expression of this gene and is associated with
myoclonus-dystonia [20], a disorder characterized by rapid muscle
contractions and repetitive movements. Loss of imprinting has also
been demonstrated in rhabdomyosarcoma tumors, in which it may be
involved in the onset and progression of the pathogenesis [21,22].
Hypermethylation of skeletal muscle ryanodine receptor gene reduces
expression of this gene and has been associated with congenital myop-
athies, such as central core disease [23].
Besides influencing gene imprinting, DNA methylation also influ-
ences the expression of many genes that are critical to skeletal muscle
development, such as the homeobox genes, T-box genes and sine
oculis-related homeobox 1, which is strongly hypermethylated; where-
as contractile fiber genes are hypomethylated [24–26]. DNA methyla-
tion is also involved in the promotion and the maintenance of muscle
stem cell renewal via hypomethylation at intragenic or intergenic
regions of the Notch receptors or Notch ligand genes in myoblasts but
not in non-muscle cells [27]. Numerous external cues influence DNA
methylation, which may determine disease onset or progression. For
instance, a high fat diet given to pregnant mice induces hypermethyla-
tion of the peroxisome proliferative activated receptor, gamma, coacti-
vator 1 alpha (PGC1α) promoter in the offspring; this epigenetic mark
is maintained until 12 months of age in the offspring and correlates
with reduced expression of PGC1α mRNA and increased metabolicdysfunctions with age [28]. Exercise during pregnancy prevents high
fat diet-induced PGC1αmethylation and increases PGC1α gene expres-
sion in the offspring, thereby reducing metabolic dysfunctions. DNA
hypermethylation has also been observed in non-CpG sites at the
PGC1α promoter in diabetic subjects and methylation levels negatively
correlate with PGC1α mRNA levels, thereby indicating that increased
promoter methylation at these loci in part regulates gene expres-
sion [29]. Besides PGC1α, exercise induces a whole genome hypome-
thylation in human skeletal muscle and dose-dependent expression of
the pyruvate dehydrogenase kinase isozyme 4, of the peroxisome
proliferator activator receptor delta and of the glucose transporter
GLUT4 [30,31]. Unlike exercise, aging significantly increases DNAhyper-
methylation throughout the genome of skeletal muscle cells, although a
direct correlation between DNA hypermethylation and the decline in
skeletal muscle mass and function associated with aging has not been
found [32]. When miss-regulated, DNA methylation may perturb
the expression of genes involved in musculoskeletal diseases.
Facioscapulohumeral muscular dystrophy (FSHD), for instance, is a
disease caused by the stable expression of an alternative full-length
mRNA form of the double homeobox 4 gene, which is sustained by
two enhancers that are hypomethylated, i.e. in a permissive transcrip-
tional state, in myoblasts of FSHD patients [33]. Abnormal levels of
mitochondrial DNA methylation and mitochondrial DNA methyltrans-
ferase Dnmt3a have also been detected in skeletal muscle of presymp-
tomatic amyotrophic lateral sclerosis (ALS) mice; these abnormalities
occur concomitantly with loss of mitochondria in myofibers [34].
Thus, further studies aimed at providing a better understanding of
DNA methylation in muscle development and homeostasis may offer
the opportunity to prevent and treat numerous muscle diseases.
3. Histone modifications
Gene activation or repression, as well as transcriptional initiation and
elongation, are regulated by many epigenetic mechanisms. With regard
to histone modifications alone, we should mention the existence of nu-
merous epigenetic marks, such as histone methylation, ubiquitylation,
phosphorylation, sumoylation, ribosylation, citrullination and acetylation,
which affect chromatin structure and, consequently, gene expression.
In the last decade, many studies have focused on the role of histone
methylation in modulating the pluripotency and lineage restriction of a
number of cells [35]. While the Polycomb Repressive Complex 2 (PRC2)
establishes gene silencing by trimethylation of histone 3 lysine 27
(H3K27me3) at developmentally regulated loci, the trithorax group,
which mediate the trimethylation of histone 3 lysine 4 (H3K4me3),
together with the lysine (K)-specific demethylase 6A and KDM1 lysine
(K)-specific demethylase 6B family, antagonize PRC2 repressive activity
and allow gene expression in specific cell types. In muscle stem cells,
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comitant presence of H3K4me3 at the transcription start sites of a
large number of genes determine and maintain the chromatin in a
primed status, thus allowing such cells to respond readily to external
stimuli [36]. Accordingly, mice lacking the enzymatic subunit of PRC2
in skeletal muscle display impaired muscle stem cell proliferation and
inappropriate gene expression, which are normally absent in muscle
cell lineages [37].
Ubiquitylation of histones influences both transcriptional initiation
and elongation, as well as transcriptional silencing in vertebrates [38],
at least in part through the promotion of H3K4me3 following
histone ubiquitylation, and H3K36me3 tri-methylation following
deubiquitylation [39]. Very little information is available on the role of
histone ubiquitylation and skeletal muscle cells. During myogenic
differentiation, histone H2B ubiquitylation levels decrease. Interesting-
ly, this reduction is impaired in muscle cells derived from “Inclusion
body myopathy with early-onset Paget disease and frontotemporal
dementia” patients [40], thus suggesting that histone ubiquitylation
plays a role in this muscular disease.
Although histone phosphorylation was reported to occur in skeletal
muscle cells bymany laboratories several years ago [41,42], its function-
al role has not yet been described. Similarly, histone sumoylation has
been associated with gene silencing through the recruitment of histone
deacetylase and heterochromatin protein 1 [43], though its effect on
skeletal muscle cells has yet to be addressed. Histone ADP-ribosylation
directly destabilizes histone–DNA interactions in the nucleosome,
therefore facilitating gene transcription in many cell types [44,45].
Many different cellular features may be influenced by histone ADP-
ribosylation, such as cell cycle progression, DNA repair and activation
of specific gene expression [46], though the role of this histone mark
in skeletal muscle is still not yet clear. Histone citrullination, in which
an arginine is converted into the amino acid citrulline, is a post-
transcriptional modification involved in chromatin decondensation
and gene regulation that has been associated with numerous disorders
[47]. The functional role of histone citrullination in skeletal muscle cells
has not yet been clarified either.
3.1. Histone acetylation
Acetylated histones represent a chromatin epigenetic tag [48]. By
removing positive charges, acetylation reduces the interactions
between histones and the DNA, thereby relaxing the DNA structure
and allowing higher levels of gene transcription. Being an essential
component of gene regulation, histone acetylation and deacetylation
are a highly dynamic process, controlled by the balance between the
antagonistic actions of the histone acetyltransferases (HATs) and the
histone deacetylases (HDACs), that influence numerous cellular path-
ways [49,50]. Depending on their protein structure and function,
HDAC proteins fall into four groups. The first two groups, i.e. class I
and class II HDACs, are considered classical HDACs whose deacetylase
activities are inhibited by the pan-HDAC inhibitor trichostatin A (TSA)
or valproic acid (VPA); the third group, i.e. the sirtuins, is a family
of NAD+-dependent deacetylases, whereas the fourth group, i.e.
HDAC11, is an atypical category that is considered to be HDAC-based
only on account of its DNA sequence similarity to other HDACs.
Biochemical analyses have revealed that the majority of HDAC activity
is due to class I HDACs, whereas highly purified recombinant class II
HDACs possess only minimal catalytic activity [51–53]. Therefore, class
II HDACs recruit members of class I HDACs on specific targets to remove
the acetyl groups from histones. Moreover, unlike class I HDACs, which
are broadly expressed, class II HDACs display relatively restricted
expression patterns [49]. Histone acetylation and deacetylation regulate
many steps ofmyogenesis in vitro, controlling the temporal hierarchical
transcription of myogenic genes, and allowing rapid transcriptional
response upon extracellular stimuli. Moreover, histone deacetylation
provides a possible explanation for the paradoxical finding that sometranscription factors are expressed in myoblasts when their target
genes have not yet been activated. For example, the initiator of the
myogenic program, MyoD, remains in a transcriptionally silent status
until myoblasts are induced to differentiate. In undifferentiated myo-
blasts, MyoD activity is repressed by HDAC1 [54], a member of class I
HDACs. Upon differentiation, HDAC1 is down-regulated, while
phospho-retinoblastoma (pRb) is hypo-phosphorylated, which allows
the formation of the pRb–HDAC1 complex in differentiating myotubes.
The pRb–HDAC1 association induces the disruption of the MyoD–
HDAC1 complex, the transcriptional activation of muscle-specific
genes, such asmuscle creatine kinase ormyogenin, andmyoblast differ-
entiation [55]. In addition, both PCAF and p300 acetylateMyoD, thereby
enhancing its transcriptional activity and allowing the recruitment and
association of HATs with muscle-specific genes, which in turn result in
the activation of MyoD-dependent genes [56–58]. Similar mechanisms
control MEF2, a transcriptional co-activator of myogenesis. Members
of class II HDACs, such as HDAC4, -5, and -7, which are expressed and
localize within the nucleus in proliferating myoblasts, associate
with and inhibit MEF2-dependent transcription, thereby blocking
MyoD-dependent conversion of fibroblasts into myotubes [59].
Upon differentiation, class II HDACs translocate into the cytoplasm,
thereby releasing the inhibition on MEF2, which promotes myoblast
differentiation (Fig. 2).
Mutantmice lacking individual HDACs are a powerful tool for defin-
ing HDAC functions in vivo. Studies of HDAC knockout mice have
revealed highly specific and crucial functions of individual HDACs in
tissue development and disease. Global deletion of a single HDAC in
mice is often lethal in the embryonic or perinatal phase owing to severe
developmental defects [60–63], thus confirming the essential role of
these enzymes in cell function and survival. Studies on tissue-specific
HDAC null mice have clarified the precise role of these proteins in
each body compartment. One study has shown that HDAC1 and 2 play
a redundant role in skeletal muscle development and homeostasis
[64], as they do in the heart. Indeed, mice lacking up to three alleles of
HDAC1 and HDAC2 in skeletal muscle are viable and display normal
muscular architecture in histological analyses. When both HDAC1 and
HDAC2 are absent in skeletal muscle, about 40% of mice die perinatally,
probably owing to respiratory defects. The remaining 60% of mutant
mice that survive the first day of life develop a progressive myopathy
characterized by degeneration of skeletal muscle and centro-nucleated
myofibers, a shift toward an oxidative metabolism and a block in
autophagy flux. The same study revealed a role of HDAC1 and HDAC2
in regulating autophagy flux in skeletal muscle and confirmed a link
between autophagy, metabolism and tissue homeostasis. Unlike
HDAC1 and HDAC2, mice lacking both HDAC4 and HDAC5 in skeletal
muscle are viable and display no apparent defects in muscle architec-
ture by histological analysis [65]. Following denervation, HDAC4 and
HDAC5 doublemutantmice preservemusclemass owing to their failure
to up-regulate the expression of myogenin and its downstream target
genes MuRF1 and atrogin1, which are responsible for muscle proteoly-
sis [66], and because they cannot activate themitogen-activated protein
kinase pathway [67]. HDAC4 has been shown to play a role in regulating
the fibroblast growth factor-mediated compensatory reinnervation of
skeletal muscle following denervation or in ALS progression [68].
Notably, HDAC4 expression in skeletal muscle of ALS patients is up-
regulated and inversely correlates with disease severity, the extent of
muscle reinnervation and functional outcome [69], thereby pointing to
the potential usefulness of class II HDAC inhibitors as a means of
improving ALS patient conditions. Accordingly, treatment with HDAC
inhibitors has also been shown to exert beneficial effects on survival
and maintenance of muscle mass in mice affected by ALS or spinal
muscular atrophy [70,71].
Systemic HDAC inhibition with pan-HDAC inhibitors improves
conditions in patients and mice in a wide range of disorders, ranging
from cancer and immunological diseases tomuscular dystrophy, cardiac
hypertrophy and neurodegenerative diseases [49,71–73]. The exact
Fig. 2. Histone acetylation and deacetylation regulate myogenesis. Histone acetylation and deacetylation are the processes by which the lysine residues in the histone core of the nucle-
osome are acetylated and deacetylated by histone acetyltransferases (HATs) and histone deacetylases (HDACs), respectively. By removing the positive charges on the histones, acetylation
allows chromatin relaxation and higher levels of gene transcription. This relaxation can be reversed by HDAC activity.
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known and numerous theories have been proposed, including changes
in gene transcription, induction of apoptosis or autophagy, and cell-
cycle arrest [74–77]. With regard to skeletal muscle, treatment with
HDAC inhibitors ameliorates Duchenne muscular dystrophy in mice.
In particular, HDAC inhibitors increase myofiber size, decrease inflam-
matory infiltrate and prevent the formation of fibrotic scars in mdx
mice [78], thereby helping to counter muscle loss and functional
decline. At the cellular level, HDAC inhibitors act on fibroadipogenic
progenitor (FAP) cells by inhibiting their adipogenic potential and
enhancing their ability to promote differentiation of adjacent satellite
cells [79]. An interesting insight into the specific role of individual
HDACs in muscular dystrophy is provided by the comparable efficacy
of a class I HDAC inhibitor and pan-HDAC inhibitors [80]. This suggests
that inhibition of class I HDACs is sufficient to exert most of the benefi-
cial effects observed in HDAC inhibitor-treatedmdxmice, which in turn
highlights the important contribution of class I HDACs to Duchenne
muscular dystrophy and muscle regeneration. Moreover, a recent
paper revealed the importance of HDAC4 in muscle regeneration [81].
Satellite cells lacking HDAC4, once isolated from mice, display re-
duced proliferation and impaired differentiation in vitro, leading to
compromised muscle regeneration in vivo. Interestingly, the lack of
HDAC4 in satellite cells is not sufficient to block their differentiation,
which implies that muscle regeneration in vivo is regulated by
HDAC4 in a paracrine/autocrine fashion. The same study provided
in vivo evidence of the positive correlation between HDAC4 levels
and the expression of Pax7 and Lix1, two genes required for correct
satellite cell proliferation, as well as of miR-133, which is required
for skeletal muscle commitment, though the molecular explanation
for the correlation between HDAC4 and these genes is still elusive
[81].Fig. 3.MicroRNA-mediated regulation of gene expression. MicroRNAs are small non-coding RN
targets. As a result, mRNA targets (e.g. Hdac4 mRNA for microRNA-206) are silenced because tGiven the dramatic phenotypes that result from HDAC gene dele-
tions, why are HDAC inhibitors so well tolerated in vivo? We propose
some explanations that are not mutually exclusive. While the genetic
deletion of a protein results in the complete absence of the specific
enzyme, HDAC inhibitors are neither specific to a single HDAC nor result
in the complete inhibition of HDAC activity, with treatment often
starting upon diagnosis of the disease. Moreover, a genetic deletion of
an HDAC eliminates the gene product permanently, whereas the action
of inhibitors is transient. Notably, HDACs participate in multiprotein
transcriptional complexes. While HDAC inhibitors are believed
to block enzymatic activity without necessarily disrupting protein
complexes, the genetic deletion of an HDAC probably perturbs the
complexes with which it is normally associated.
4. MicroRNAs as additional tool of epigenetic control
MicroRNAs (miRNAs) are a class of small non-coding RNAs that
negatively regulate gene expression by pairing their nucleotides
2–8 at the 5′ end, known as the “seed region”, with sequences located
predominantly in the 3′ UTRs of target mRNAs [82] (Fig. 3). The crucial
role of miRNAs in mouse development is proved by the genetic muta-
tion in the miRNA processing enzyme Dicer in all the tissues, which
results in embryonic death [83]. Moreover, numerous types of disorders
are associatedwith changes in the amount ofmiRNA in tissues and/or in
levels of serum circulating miRNAs, which suggests that it may be
possible to usemiRNAs as new and valuable biomarkers for the diagno-
sis of a range of diseases [84–88].
MiRNAs play a crucial role in skeletal muscle development, as
demonstrated by the perinatal death due to skeletal muscle hypoplasia
of the skeletal muscle-specific null mice for Dicer [89]. Skeletal muscle-
specific null mice for single miRNAs have been developed and analyzedA molecules that function via base-pairing with complementary sequences within mRNA
hey can no longer be translated into proteins.
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skeletal muscle development reflects requisite roles of specific miRNAs
or multiple miRNAs. MyomiRs are miRNAs expressed in striated
muscle; they include miR-1, miR-133a, miR-206, miR-208a, which is
cardiac-specific, and miR-208b, miR-499 and miR-486 [90–94]. The
expression of over one hundred miRNAs is modulated in different
ways in murine myoblasts and in myotubes in vitro [95], thus suggest-
ing thatmiRNAs are critical regulators of skeletal muscle differentiation.
Indeed, several miRNAs have been implicated in the regulation of
myoblast activation, proliferation and differentiation, as well as in the
maintenance of the myogenic lineage in vitro. MiR-489, which
suppresses the expression of the oncogene DEK [96], and miR-31,
which inactivates the transcription of the myogenic factor Myf5 [97],
ensure the maintenance of muscle stem-cell quiescence, thereby
preventing precocious myogenic differentiation. Myoblast proliferation
is promoted and maintained by the combined actions of miR-27a/b,
which inhibit myostatin and Pax3 protein levels [98,99], miR-133a,
which targets serum response factor [100], andmiR-682 [101].Whereas
myoblast differentiation and fusion into myotubes are promoted by
miR-206, which inhibits the expression of a number of negative regula-
tors of myogenesis, such as notch3, igfbp5, Meox2, RARB, Fzd7,
MAP4K3, CLCN3, NFAT5 and the tissue inhibitor of metalloproteinase
3 [102–105]. Moreover, in differentiating myoblasts, the repression of
TGF-beta signaling, a repressor of myoblast differentiation, is ensured
by the combined action of miR-206 and miR-29, which inhibit Smad3
expression [106], and miR-26a, which represses Smad1 and Smad4
expression [107], ultimately leading tomyoblast differentiation. Besides
promoting myoblast differentiation, together with miR-128a and miR-
1, miR-206 helps to block cell proliferation by inhibiting the expression
of several genes involved in the insulin signaling pathway, as well as
Pax7 expression [107–109]. Indeed, inhibition of miR-1 and miR-206
leads to increased Pax7 protein levels and myoblast proliferation;
conversely, loss of miR-1 and miR-206 reduces Pax7 expression and
myoblast differentiation [105,108]. Inhibition of cell proliferation
and promotion of myoblast differentiation are also mediated by
miR-26a and miR-1, which repress Ccnd1 expression [110], and
miR-133a/b, which negatively regulates FGFR1 and PP2AC proteins
[111]. As myoblasts differentiate, the downregulation of the enzy-
matic subunit of the PRC2, Ezh2, and its partner YY1 is mediated by
the combined action of miR-214 [112], miR-26a [113] and miR-29
[114], thereby relieving PRC2-mediated repression of muscle genes.
An important role in promoting myoblast differentiation has also
been described for miR-133a, which modulates the IGF-1 receptor
[115] and sarcomeric actin organization [116]. Moreover, by
targeting PRDM16, a master gene for brown fat determination,
miR-133 modulates the choice between myogenic and brown adi-
pose lineage [117]. Besides myomiRs, whose expression is up-
regulated during muscle differentiation, there are other miRNAs
that participate in myogenesis by relieving the expression of muscle
specific genes, such as miR-23a, which directly regulates the expres-
sion of myosin heavy chain genes [118].Table 1
Summarizing table with examples of the relevant skeletal muscle genes regulated through DN
Gene symbol Epigenetic regulation
Peg3 Hypermethylation
Sgce Loss of methylation
H19, IGF2 Loss of methylation
Ryr1 Hypermethylation
Six1; Pax3; Tbx1 Hypermethylation
Obscn; Myh7b Hypomethylation
NOTCH1; NOTCH2; JAG2; DLL1 Hypomethylation
PGC-1alpha Hypermethylation
DUX4 Hypomethylation
Ckm; Myog Deacetylation
Dach2 DeacetylationDespite the importance miRNAs play in regulating myogenesis
in vitro, surprisingly little impact has been observed on skeletal muscle
phenotype following the deletion of the majority of miRNAs in mice
[94]. This is in keeping with the role of miRNAs as stress mediators
that restore cell homeostasis by finely regulating gene expression [119].
For instance, althoughmiR-206 null mice develop healthy and function-
al skeletalmuscle, upon stressmiR-206 is required for efficient regener-
ation of neuromuscular synapses following denervation and for correct
satellite cell differentiation and muscle regeneration [68,105]. More-
over, the absence of miR-206 accelerates ALS progression and exacer-
bates the dystrophic phenotype in mice [68,105]. Mice lacking either
miR-133a-1 or miR-133a-2 are normal; conversely, double mutant
mice develop centronuclearmyopathy in fast-twitchmyofibers, accom-
panied by impaired mitochondrial function and fast-to-slow myofiber
conversion [120], thereby revealing the essential role of miR-133a in
multiple facets of skeletal muscle function and homeostasis in mice. It
is not clear why knockout mice do not display a more dramatic pheno-
type, as would be expected from in vitro studies. One possible explana-
tion is that myomiRs are redundant in regulating the same target genes,
including miR-1 and miR-206. Therefore, the lack of a single miRNA
might be compensated for by the presence of another family member,
thus preventing any deleterious phenotype resulting from the miRNA
knockout. This hypothesis is supported by the fact that only the double
knockout of the two family members, miR-133a-1 and miR-133a-2,
reveals an evident phenotype in striated muscle. In skeletal muscle,
miR-208b and miR-499 are encoded in introns of two myosin heavy
chain genes, respectively Myh7 andMyh7b, which in turn control mus-
cle myosin content and myofiber identity. Similarly to miR-133a-1 and
miR-133a-2, in vivo studies have shown that miR-208b and miR-499
play redundant roles in the specification of muscle fiber identity by
activating slow and by repressing fast myofiber gene programs, thereby
ultimately affecting muscle performance [93]. Despite the efforts of
numerous studies, the role of miRNA in skeletal muscle development
and diseases has still been partially elucidated, given the numerous
possible interactions between transcription factors, miRNAs and their
target mRNAs. Further studies are needed to characterize the in vivo
functions of miRNAs and to identify their downstream target genes.
5. Conclusions
Although we do not yet know the precise mechanisms underlying
epigenetic gene regulation in the pathogenesis of several diseases, the
finding that the progression of such diseases can be altered bymodulat-
ing epigenetic programs, via HDAC inhibitors, antimiRs or miRNA
mimics, is highly promising for medical purposes. Epigenetics provides
another level of regulation that, combined with genetic differences,
might mediate the relationship between genotype and environmental
factors (Tables 1 and 2). Thus, the epigenetic component might help
to explain themarked age-related increase in the incidence of common
diseases, aswell as the frequent discordance of diseases betweenmono-
zygotic twins. Since epigenetics is one of the main causes of phenotypicA methylation and acetylation that are reviewed in the text.
Functional output References
Skeletal muscle atrophy [16]
Myoclonus-dystonia [20]
Rhabdomyosarcoma [21,22]
Core myopathies [23]
Skeletal muscle development [23–25]
Skeletal muscle development [25]
Specification of muscle stem cells [27]
Metabolic dysfunctions [28,29]
Facioscapulohumeral muscular dystrophy [33]
Block of myoblast differentiation [59]
Neurogenic muscle atrophy [66]
Table 2
Summarizing table with examples of relevant miRNAs regulating skeletal muscle genes that are reviewed in the text.
miRNA nomenclature Target gene symbol Functional output References
miR-489 DEK Muscle stem cell quiescence [96]
miR-31 Myf5 Muscle stem cell quiescence [97]
miR-27 a/b Mstn Pax3 Myoblast proliferation [98,99]
miR-133a SRF, IGF-1 Myoblast proliferation [114,115]
miR-133 a/b FGFR1, PP2AC, PRDM16 Myoblast differentiation [110,116]
miR-206 Notch3, igfbp, Meox2, RARB, Fzd7,
MAP4K3, CLCN3, NFAT5, Mstn, Smad3, Pax7
Myoblast differentiation [102–105,108]
miR-29 Smad3, YY1 Myoblast differentiation [106,114]
miR-26a Smad1, Smad4, Ccnd1, Ezh2 Myoblast differentiation [107,109,112]
miR-128a Pax7 Myoblast differentiation [109]
miR-1 Pax7, Ccnd1 Myoblast differentiation [108]
miR-214 Ezh2, YY1 Myoblast differentiation [112]
miR-23a Myh 1,2,4 Myoblast differentiation [118]
314 V. Moresi et al. / Biochimica et Biophysica Acta 1849 (2015) 309–316variation in physiological and pathological conditions, our understand-
ing of and ability tomanipulate the epigenomeholds enormouspromise
for preventing and treating illness.
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